Results 161 to 170 of about 161,428 (309)

Efficacy of House Dust Mite Immunotherapy in Chinese Allergic Rhinitis Patients With Diverse Sensitization Patterns: A Multicenter Study (COVER Study)

open access: yesAllergy, EarlyView.
This prospective multicenter study corroborates the efficacy of AIT with the native HDM allergen extract in Chinese AR patients with diverse HDM sensitization patterns. HDM sensitization pattern affects the efficacy of AIT, with patients sensitized to both major and minor allergens of HDM showing improved outcomes with HDM SCIT.
Qingxiu Xu   +14 more
wiley   +1 more source

The prevalence of sensitization and relevant symptoms of allergic rhinitis in an unselected Belgium population [PDF]

open access: yes, 2010
Acke, Frederic   +6 more
core   +1 more source

Peanut Component‐Specific IgE and IgG4 Are Modulated by Sublingual Immunotherapy and Are Associated With Remission in 1–4‐Year‐Old Children

open access: yesAllergy, EarlyView.
This study presents a post hoc analysis of longitudinal changes in peanut component‐specific IgE and IgG4 in children aged 1–4 years undergoing peanut SLIT, aiming to uncover immune mechanisms and potential biomarkers of remission. Peanut SLIT reduced IgE and increased IgG4 responses to Ara h 1, Ara h 2, Ara h 3, and Ara h 6.
Neel Singh   +9 more
wiley   +1 more source

Oral Immunotherapy Induces Shift in lncRNA Expression Modulating Allergen‐Specific Immune Responses

open access: yesAllergy, EarlyView.
We used PBMC transcriptome from 50 hen's egg‐allergic patients to study the role of lncRNA in OIT. Positive correlation was found between 17 lncRNAs and the IL‐4/IL‐13 pathway in vivo, and the expression of the selected lncRNA aligned with CXCL8 upon PBMC egg‐restimulation.
Olivia Liong   +5 more
wiley   +1 more source

Long‐Term Efficacy and Safety of Ligelizumab as Re‐Treatment in Patients With Chronic Spontaneous Urticaria

open access: yesAllergy, EarlyView.
Ligelizumab re‐treatment in CSU patients showed sustained efficacy and tolerability. Over 50% achieved symptom control (UAS7 ≤ 6) by Week 12; benefits maintained through Week 52. No new safety signals observed; aligns with prior PEARL trial outcomes. CSU, chronic spontaneous urticaria; mg, milligram; q4w, every 4 weeks; UAS, urticaria activity score ...
Ana M. Gimenez‐Arnau   +22 more
wiley   +1 more source

Five‐Grass‐Pollen Sublingual Immunotherapy Drops Are Efficacious and Well Tolerated in Adults: The RHAPSODY Phase III Trial

open access: yesAllergy, EarlyView.
The RHAPSODY multinational study investigated 26 months of continuous treatment with 5‐grass‐pollen sublingual SLIT drops in adults with moderate‐to‐severe grass‐pollen‐induced allergic rhinoconjunctivitis. The primary efficacy endpoint (the average daily total combined score) showed statistically significant differences in favour of the active ...
Alain Didier   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy